Katherine Vega Stultz

Ms. Stultz is an experienced life science executive leader and director for both private and public companies. She is known for her tenacity in building organizations through both company and product lifecycle evolution including clinical development strategy; commercialization pre and post launch; portfolio management; corporate governance; company scaling; financing and fundraising; P&L accountability; integrations and restructuring. She has scaled organizations to be fit for purpose and drive company value. She has launched several multi-billion products and directed a clinical project organization worldwide overseeing over 30 mid/late-stage clinical programs across hematology and oncology portfolio, developed strategies in cell and gene therapy and advanced development in liver disease. She currently serves as President and CEO for BrainXell Therapeutics Global, a company focused on iPSC therapeutic advancement in neuroscience. Previously she served as President and CEO of Ocelot Bio a Series A company, COO of Graphite Bio advancing the company from Series A to IPO, and in her 15 years at Celgene served as Corporate Vice President, Global Project & Portfolio Management and a General Manager. Her early career was at Eli Lilly & Company and prior to this ConvaTec, a former BMS company. She received her degree in Mechanical Engineering with a concentration in Biomedical Sciences from Cornell University. Ms. Stultz is a frequent speaker on industry trends, leadership, and development.